NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP is investigating potential claims against the Board of Directors of KYTHERA Biopharmaceuticals, Inc. (“KYTHERA” or the “Company”) (NASDAQ:KYTH) concerning the proposed acquisition of the Company by Allergan plc (“Allergan”). Pursuant to the terms of the definitive merger agreement, KYTHERA stockholders will have the right to receive $75.00 in a combination of cash and shares of Allergan common stock for each share of Kythera common stock they own,